In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir. The Indian ...

Lenacapavir, one of several HIV drugs in Gilead's portfolio, met its key endpoints in a late-stage clinical trial. It did even better than Gilead's classic HIV treatment. Gilead's news was that ...

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...

Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company will next seek approval from the U.S. Food ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...

High-rolling investors have positioned themselves bullish on Gilead Sciences GILD, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

There was some good news in the clinical sphere for Gilead Sciences (NASDAQ: GILD) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of ...